Spread the Word
Campaign Insider Campaign Insider is the blog from Politics magazine, featuring tips and insights from the industry's best consultants and analysts.

Sign up with a new campaign? Hire a new staff member? Got a news tip? Drop us a line at press@politicsmagazine.com.






SOCIAL NETWORKS

 
Add to Technorati Favorites
Healthcare Roundtable: PhRMA Says 'We Gave Plenty'
Written by Shane D'Aprile on October 07, 2009, 01:39 PM
Amidst increasing criticism from members of Congress that the White House hasn’t won enough concessions from the pharmaceutical industry on healthcare reform, PhRMA’s Christopher Badgley fired back Wednesday at a healthcare forum hosted by Politics magazine. Badgley, the vice president of state government affairs at PhRMA, says his industry has brought more to the table than it ever wanted to, anchored by the industry’s promise to find $80 billion in savings on prescription drugs over the next decade.

“Our agreement is a good contribution from the industry,” Badgley told Politics. “$80 billion over ten years is the agreement the White House dragged us to. We didn’t go in and say, ‘Oh, by the way, we want to be regulated more and we want to give you $80 billion.’ We certainly didn’t want to go that high.”

The critique from many Congressional Democrats—as well as from a handful of Republicans—stems from the White House’s decision to abandon two provisions that PhRMA steadfastly opposed. The first would allow the importation of drugs from other countries, including Canada. The second would give the government the ability to negotiate prescription drug prices for Medicare recipients.

North Dakota Democrat Byron Dorgan plans to offer an amendment on the Senate floor to allow the importation of cheaper prescription drugs from other nations.

At Wednesday’s healthcare roundtable, which was co-hosted by Pharmacy Times and The American Journal of Managed Care, Badgley said he’s hopeful the provision won’t pass and criticized the proposal for what he called a lack of protections against counterfeiters.

“If you look at a lot of the importation proposals, including the Dorgan one, there’s very little protection, whether it be from counterfeiters in China, Bulgaria, Pakistan. There’s not enough to prevent the types of products that could pose significant risks from getting into our delivery system,” Badgley said.

Sen. Dorgan’s office has yet to respond to a request for comment, but Senate Majority Leader Harry Reid said last week that Dorgan’s amendment would be among the first voted on once the bill gets to the floor.

Shane D’Aprile is senior editor at Politics magazine.
He can be reached at sdaprile@politicsmagazine.com

Blog Comments

c
The Single Payer argument is that we can cover everyone well at equal or less cost by doing two things: reducing overhead like with Medicare and like foreign competitors and by negotiating with Big Pharma , like every other foreign country. A silence and an "inside game" about the drug issue may have shielded Democrats from the Single Payer logic.
craig
On the other hand you don't want to take on two monsters at the same time(big insurance and big pharma.)Obama is big but not stupid.

New Comment




simple_captcha.jpg
(type the code from the image)